Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MTOPF$0.020.00(0.00%)Barbrook Gold Mine Business Rescue Plan is Advancing - Lions Bay Resources Corrects Misleading Vantage Goldfield Claims[8:04:00 AM ET]AMTX$1.35+0.04(+3.05%)Aemetis to Review Third Quarter 2026 Financial Results on November 5, 2026[8:03:22 AM ET]SATL$4.00+0.05(+1.27%)Satellogic Schedules Third Quarter 2026 Results Conference Call on Tuesday, November 10, 2026, at 4:30 p.m. Eastern Time[8:00:00 AM ET]BA$168.04-0.14(-0.08%)Boeing: Global Freighter Fleet to Exceed 4,000 Airplanes as Air Cargo Traffic Doubles by 2045 Boeing [NYSE: BA] projects in its 2026 World Air Cargo Forecast that air cargo traffic will double over the next 20 years, driving the freighter...[8:00:00 AM ET]BCAL$21.59-0.36(-1.64%)CALIFORNIA BANCORP REPORTS THIRD QUARTER EARNINGS, HIGHLIGHTED BY STEADY LOAN GROWTH AND STRONG DEPOSIT GROWTH[8:00:00 AM ET]ECOR$7.61+0.17(+2.28%)electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)[8:00:00 AM ET]WING$130.00+6.48(+5.25%)Wingstop Inc. Reports Fiscal Third Quarter Financial Results Wingstop Inc. (NASDAQ: WING) today announced financial results for the fiscal third quarter ended September 26, 2026. "We are taking deliberate...[8:00:00 AM ET]SNES$0.84-0.01(-1.26%)SenesTech: Sandstrom Partners Hired As Strategic Advisor on Marketing and Branding[8:00:00 AM ET]OSS$7.29+0.53(+7.84%)One Stop Systems Reports Q3 2026 Results[8:00:00 AM ET]KTOS$41.68+0.37(+0.88%)Kratos Receives $33.6 Million Contract to Provide Power Conversion System for NASA’s Historic SR-1 Freedom Nuclear-Powered Spacecraft[8:00:00 AM ET]BNTC$8.80+0.12(+1.38%)Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301[8:00:00 AM ET]WAT$467.90+11.92(+2.61%)Waters Launches AI-Powered Peak Integration Expanding its Suite of Premium AI Subscription Capabilities for Empower Software Waters Corporation (NYSE: WAT) today announced AI-Powered Peak Integration, the next step in its strategy to build intelligent AI, machine learning,...[8:00:00 AM ET]SCOR$3.25+0.12(+3.67%)Proximic by Comscore Expands Integration Across Magnite's CTV Ecosystem[8:00:00 AM ET]URGN$34.60+0.69(+2.03%)UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer[8:00:00 AM ET]

AXGN · NASDAQ

AxoGen, Inc.

$44.06 +6.67 (+17.84%)

Company overview

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ
Market cap
$2.6B
Employees
451
Headquarters
Alachua, FL
Website
axogeninc.com
CEO
Michael D. Dale
Listed
December 17, 1986
P/E
-69.60
Dividend yield
22.22%

Company financials

Revenue
$238M
Gross profit
$179M
Operating income
-$9M
EBITDA
$5.7M
Net income
-$31.5M
EPS
-$0.63
Total assets
$289M
Total debt
$20.6M
Gross margin
75.01%
Net margin
-13.21%
Earnings yield
-1.44%

Revenue segmentation

By product (FY 2025)

No product segmentation.

By region (FY 2025)

Showing FY 2025

Price chart

33.3638.4343.5148.5953.66
AXGN 1D NASDAQ O38.14H39.04L37.31C37.39-0.63 (-1.66%)Vol756.36K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
AXGNAxoGen, Inc. Press release Axogen, Inc. Reports Third Quarter 2026 Financial Results GlobeNewswire
AXGNAxoGen, Inc. Stock news GMED or AXGN: Which Is the Better Value Stock Right Now? Zacks Investment Research
AXGNAxoGen, Inc. Press release Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026 GlobeNewswire
AXGNAxoGen, Inc. Stock news This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Benzinga
AXGNAxoGen, Inc. Stock news Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN) Zacks Investment Research
AXGNAxoGen, Inc. Stock news Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week PRNewsWire
AXGNAxoGen, Inc. Press release Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair GlobeNewsWire
AXGNAxoGen, Inc. Stock news Axogen Inc (AXGN) Shares Fall 3.0% -- GF Value Says Still Overvalued GuruFocus
AXGNAxoGen, Inc. Stock news Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair Benzinga
AXGNAxoGen, Inc. Stock news 2 Medical-Device Stocks Lighting Up the Options Pits Schaeffers Research
AXGNAxoGen, Inc. Stock news Axogen, Inc. (AXGN) M&A Call Transcript Seeking Alpha
AXGNAxoGen, Inc. Press release Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock GlobeNewswire
AXGNAxoGen, Inc. Press release Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies GlobeNewsWire
AXGNAxoGen, Inc. Press release Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference GlobeNewswire
AXGNAxoGen, Inc. Stock news Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100 GuruFocus
AXGNAxoGen, Inc. Stock news Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026 Globe News Wire
AXGNAxoGen, Inc. Press release Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026 GlobeNewsWire
AXGNAxoGen, Inc. Stock news Eli Lilly Leads Medical Stocks To Watch, While Google Finds Support Investors Business Daily
AXGNAxoGen, Inc. Stock news AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound Investors Business Daily
AXGNAxoGen, Inc. Stock news AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam MarketBeat
See more
FAQ

Questions about AxoGen, Inc.

What does AxoGen, Inc. do?
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
What is AXGN's market cap?
AxoGen, Inc. (AXGN) is a listed stock with a live quote. The latest market cap on this page is $2.6B.
Where is AxoGen, Inc. headquartered?
AxoGen, Inc. is headquartered in Alachua, FL.
How do I get AXGN news from the API?
Call GET /v1/news?tickers=AXGN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does AXGN news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AXGN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the AXGN price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs